NYMX - Nymox Pharmaceutical Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.9250
+0.0050 (+0.26%)
As of 2:04PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.9200
Open1.9266
Bid1.9200 x 800
Ask1.9400 x 1000
Day's Range1.9050 - 1.9400
52 Week Range1.2500 - 4.3500
Volume31,502
Avg. Volume87,950
Market Cap130.277M
Beta (3Y Monthly)2.67
PE Ratio (TTM)N/A
EPS (TTM)-0.1750
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.25
Trade prices are not sourced from all markets
  • GlobeNewswire7 days ago

    Nymox Reports Pre-NDA CMC Meeting with the FDA

    Nymox Pharmaceutical Corporation (NYMX) today announced that it has held its pre-New Drug Application (NDA) Chemistry Manufacturing and Controls (CMC) meeting with the US Food and Drug Administration (FDA) regarding its lead product candidate Fexapotide Triflutate, a novel prostate injectable developed for the treatment of enlarged prostate (Benign Prostatic Hyperplasia, BPH). The purpose of the April 15 meeting was to discuss the CMC data package for Fexapotide, an important regulatory requirement prior to the NDA submission. Nymox is pleased to report that it considers the meeting was constructive and positive.

  • GlobeNewswirelast month

    Nymox Teleconference Monday, March 25 10:00 a.m. EDT

    HASBROUCK HEIGHTS, N.J., March 21, 2019 -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) Nymox will hold a teleconference for shareholders on Monday, March 25 at 10:00 a.m..

  • GlobeNewswirelast month

    Nymox Announces Appointment of Mark Staples PhD as Vice President of Chemistry, Manufacturing and Controls (CMC) 

    Nymox Pharmaceutical Corporation (NYMX) is pleased to announce that Mark Staples PhD has joined Nymox as Vice President for Chemistry, Manufacturing, and Controls (CMC). During his career Dr Staples has led innovative pharmaceutical development teams, supervised successful CMC modules of regulatory filings for drugs and biologics, managed technology transfer to production facilities, and functioned in upper management in a variety of senior positions. Dr Staples held senior positions with highly successful biopharmaceutical companies such as Biogen and other well-known corporations.

  • Introducing Nymox Pharmaceutical (NASDAQ:NYMX), The Stock That Slid 60% In The Last Five Years
    Simply Wall St.last month

    Introducing Nymox Pharmaceutical (NASDAQ:NYMX), The Stock That Slid 60% In The Last Five Years

    It is a pleasure to report that the Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is up 36% in the last quarter. But that can't change the reality that over the longer termRead More...

  • GlobeNewswirelast month

    Nymox Announces Appointment of Russell Thomson Ph.D. as Director of Quality and EU Qualified Person for Company's Manufacturing Operations

    Nymox Pharmaceutical Corporation (NYMX) is pleased to announce the new appointment of Russell I. Thomson PhD, FRSC, as the Company's Director of Quality and EU Qualified Person, for all of Nymox's Chemistry, Manufacturing and Controls Operations.  Dr Thomson is an authority in the field of Quality Assurance and Control in the Chemical and Pharmaceutical Industries. Dr. Thomson is a Fellow of the Royal Society of Chemistry (UK), a Chartered Chemist and Chairman of the Royal Society of Chemistry Qualified Persons Assessors Panel.  He has worked in the pharmaceutical industry in positions including Head of Quality and Director of QA and Regulatory Affairs, and as Consultant Qualified Person at numerous large and small drug manufacturing facilities in the EU and the US for over 20 years.  Dr. Thomson was a Chartered Scientist with The Science Council (UK) from 2004-2010 and Corporate Member of the South African Chemical Institute from 1980-1999.

  • GlobeNewswirelast month

    Nymox to Host Investor Teleconference

    Management will discuss the Company's current business progress with an update on its regulatory submission activities in the US and EU. To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements.

  • Does The Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Share Price Fall With The Market?
    Simply Wall St.3 months ago

    Does The Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Share Price Fall With The Market?

    If you own shares in Nymox Pharmaceutical Corporation (NASDAQ:NYMX) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...

  • GlobeNewswire3 months ago

    New Peer Review Article Entitled “Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia” Published in Therapeutic Advances in Urology

    HASBROUCK HEIGHTS, N.J., Jan. 15, 2019 -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reports today that a new peer review article has been published in Therapeutic.

  • GlobeNewswire4 months ago

    2018: A Year of Achievements for NYMOX

    HASBROUCK HEIGHTS, N.J., Dec. 19, 2018 -- Following the Nymox (NASDAQ: NYMX) Annual General Meeting yesterday (December 18, 2018), Nymox management discussed many significant.

  • Simply Wall St.4 months ago

    Are Insiders Selling Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Stock?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mention Read More...

  • Associated Press5 months ago

    Nymox: 3Q Earnings Snapshot

    The St. Laurent, Quebec-based company said it had a loss of 5 cents per share. The biopharmaceutical company posted revenue of $40,000 in the period. In the final minutes of trading on Tuesday, the company's ...

  • Associated Press8 months ago

    Nymox: 2Q Earnings Snapshot

    On a per-share basis, the St. Laurent, Quebec-based company said it had a loss of 4 cents. The biopharmaceutical company posted revenue of $88,000 in the period. In the final minutes of trading on Monday, ...

  • What You Must Know About Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) Major Investors
    Simply Wall St.last year

    What You Must Know About Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) Major Investors

    In this article, I’m going to take a look at Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...